Ofwat could be scrapped in water reforms
Former Bank of England governor Sir Jon Cunliffe will publish the findings of the Independent Water Commission on Monday, with stakeholders across the industry expecting significant changes to regulation to be at its heart.
The existing regulator Ofwat has been under fire from all sides in recent years amid rising public anger at levels of pollution and the financial management of water companies.
Read more:
Campaigners and politicians have accused Ofwat of failing to hold water operators to account, while the companies complain that its focus on keeping bills down has prevented appropriate investment in infrastructure.
In an interim report, published in June, Sir Jon identified the presence of multiple regulators with overlapping responsibilities as a key issue facing the industry.
While Ofwat is the economic regulator, the Environment Agency has responsibility for setting pollution standards, alongside the Drinking Water Inspectorate.
Sir Jon's final report is expected to include a recommendation that the government consider a new regulator that combines Ofwat's economic regulatory powers with the water-facing responsibilities currently managed by the EA.
In his interim report Sir Jon said options for reform ranged from "rationalising" existing regulation to "fundamental, structural options for integrating regulatory remits and functions".
He is understood to have discussed the implications of fundamental reform with senior figures in industry and government in the last week as he finalised his report.
Environment Secretary Steve Reed is expected to launch a consultation on the proposals following publication of the commission report.
The commission is also expected to recommend a "major shift" in the model of economic regulation, which currently relies on econometric modelling, to a supervisory approach that takes more account of individual company circumstances.
Read more from Sky News:
Sir Jon has said the water industry requires long-term strategic planning and stability in order to make it attractive to "low-risk, low-return investors".
The water industry has long complained that the current model, in which companies are benchmarked against a notional model operator, and penalised for failing to hit financial and environmental standards, risks a "doom loop".
Thames Water, currently battling to complete an equity process to avoid falling into special administration, has said the imposition of huge fines for failing to meet pollution standards is one of the reasons it is in financial distress.
Publication of the Independent Commission report comes after the Environment Agency published figures showing that serious pollution incidents , and as Thames Water imposes a hosepipe ban on 15m customers.
Ofwat, Water UK and the Department for the Environment all declined to comment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
RBC Capital Reiterates a Hold Rating on BP p.l.c. (BP), Sets a £4.50 Price Target
BP p.l.c. (NYSE:BP) is one of the best . On July 16, RBC Capital analyst Biraj Borkhataria maintained a Hold rating on BP p.l.c. (NYSE:BP) and set a price target of £4.50. Workers in hard hats and safety gear processing oil and gas in a US refinery. BP p.l.c. (NYSE:BP) reported $1.4 billion in underlying replacement cost profit in fiscal Q1 2025, compared to $1.2 billion in the previous quarter. Operating cash flow for the quarter reached $2.8 billion, including a working capital build of $3.4 billion and around $4.6 billion lower than the previous quarter. The drop reflects the effects of seasonal inventory and the timing of a number of payments, including payments related to low-carbon assets held for sale and annual bonus payments. BP p.l.c. (NYSE:BP) also reported $27.0 billion net debt at the end of fiscal Q1 2025, driven primarily by lower operating cash flow. Headquartered in London, United Kingdom, BP p.l.c. (NYSE:BP) is an integrated oil and gas company that provides carbon products and services. Its operations are divided into the Gas and Low Carbon Energy, Oil Production and Operations, and Customers and Products segments. While we acknowledge the potential of BP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
19 minutes ago
- Yahoo
BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510
GSK plc (NYSE:GSK) is one of the best . On July 15, BofA analyst Sachin Jain maintained a Sell rating on GSK plc (NYSE:GSK) and set a price target of p1,510.00. A doctor and a patient discussing a therapy plan that includes pharmaceutical products. The analyst based the rating on factors related to the company's Blenrep drug, stating that the FDA briefing documents highlighted considerable concerns regarding its ocular toxicity and dosing. Issues associated with these factors are central, and the FDA questioned if suitable dosages have been identified, given the poor tolerability seen in trials. The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are especially alarming, as a majority of the patients experienced severe and recurrent ocular events. Jain also noted the limited applicability of trial results to the US markets because of the use of a comparator arm not approved in the US and low enrollment of US patients, resulting in an uncertain risk-reward balance for the drug and warranting a cautious stance. Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Starmer holds ‘constructive' call with Taoiseach on Troubles legacy plans
Sir Keir Starmer stressed the importance of 'consensus' in handling the legacy of the Troubles as he spoke to his Irish counterpart on Friday. In a phone call with Taoiseach Micheal Martin, the Prime Minister had what Downing Street described as a 'constructive discussion' on dealing with the legacy of the 30-year conflict in Northern Ireland. A Number 10 spokesperson said the two men had 'underscored the importance of a way forward that built consensus', before turning to economic issues and the UK-EU relationship. Mr Martin himself echoed Downing Street's comments, tweeting that he had had a 'constructive discussion with British PM Keir Starmer today on a framework for dealing with legacy'. The call came as Sir Keir faces pressure from some of his own backbenchers over plans to repeal and replace legislation passed by the previous government that halted investigations into all but the most serious allegations involving Troubles-related cases. The Northern Ireland Troubles (Legacy and Reconciliation) Act has been criticised by human rights campaigners for granting conditional immunity to suspects. That provision was ruled incompatible with human rights laws by the Northern Irish courts, prompting Labour to commit to replacing legislation it described as 'flawed and failed'. But that proposal has brought condemnation from former British soldiers who fear it will open the way to vexatious prosecutions and civil claims. Opponents are also reported to include some Labour MPs, including veterans minister Al Carns. A former Royal Marine and special forces officer, Mr Carns was reported by The Times to be considering resigning over plans to repeal the Legacy Act. But earlier in the week, Downing Street said the Government was 'working in lockstep' on the issue. A Ministry of Defence source also played down the prospect of Mr Carns quitting, but told the PA news agency it was a 'tricky issue' and 'when you are making policy there is always going to be debate internally'.